Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial (vol 8, e000891, 2020)

被引：0
|
作者：
Motzer, R. J.
Escudier, B.
McDermott, D. F.
机构：
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷 / 05期
关键词：
D O I：
10.1136/jitc-2020-000891corr1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.
    Burotto, Mauricio
    Powles, Thomas
    Escudier, Bernard
    Apolo, Andrea B.
    Bourlon, Maria Teresa
    Shah, Amishi Yogesh
    Suarez, Cristina
    Porta, Camillo
    Barrios, Carlos H.
    Richardet, Martin
    Gurney, Howard
    Kessler, Elizabeth R.
    Tomita, Yoshihiko
    Bedke, Jens
    George, Saby
    Scheffold, Christian
    Wang, Peter
    Fedorov, Viktor
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [32] Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial (vol 41, pg 603, 2023)
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (21) : 3767 - 3767
  • [33] Nivolumab plus cabozantinib (N plus C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.
    Apolo, Andrea B.
    Powles, Thomas
    Burotto, Mauricio
    Bourlon, Maria Teresa
    Hsieh, James J.
    Basso, Umberto
    Shah, Amishi Yogesh
    Suarez, Cristina
    Porta, Camillo
    Barrios, Carlos H.
    Gurney, Howard
    Kessler, Elizabeth R.
    Retz, Margitta
    George, Saby
    Escudier, Bernard
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Pembrolizumab plus axitinib versus sunitinib monotherapy as firstline treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (vol 21, p1563, 2020)
    Powles, T.
    Plimack, E. R.
    Soulieres, D.
    LANCET ONCOLOGY, 2020, 21 (12): : E553 - E553
  • [35] Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study
    Gruenwald, V.
    Powles, T.
    Kopyltsov, E.
    Kozlov, V.
    Alonso-Gordoa, T.
    Eto, M.
    Hutson, T.
    Motzer, R.
    Winquist, E.
    Maroto, P.
    Keam, B.
    Procopio, G.
    Wong, S.
    Melichar, B.
    Rolland, F.
    Oya, M.
    Rodriguez-Lopez, K.
    Saito, K.
    McKenzie, J.
    Porta, C.
    ONKOUROLOGIYA, 2023, 19 (04): : 32 - 43
  • [36] Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study
    Grunwald, Viktor
    Powles, Thomas
    Kopyltsov, Evgeny
    Kozlov, Vadim
    Alonso-Gordoa, Teresa
    Eto, Masatoshi
    Hutson, Thomas
    Motzer, Robert
    Winquist, Eric
    Maroto, Pablo
    Keam, Bhumsuk
    Procopio, Giuseppe
    Wong, Shirley
    Melichar, Bohuslav
    Rolland, Frederic
    Oya, Mototsugu
    Rodriguez-Lopez, Karla
    Saito, Kenichi
    McKenzie, Jodi
    Porta, Camillo
    EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (04): : 437 - 446
  • [37] Final prespecified overall survival (OS) analysis of the phase 3 CLEAR trial: 4-year follow-up of lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in patients with advanced renal cell carcinoma (aRCC)
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Grunwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Merchan, Jamie R.
    Goh, Jeffrey C.
    De Giorgi, Ugo
    Melichar, Bohuslav
    Hong, Sung-Hoo
    Gurney, Howard
    Rodriguez-Lopez, Karla
    He, Cixin S.
    Okpara, Chinyere E.
    McKenzie, Jodi
    Choueiri, Toni K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 72 - 73
  • [38] Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
    Tran, Benjamin Duy
    Li, Jing
    Ly, Neang
    Faggioni, Raffaella
    Roskos, Lorin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (02) : 179 - 189
  • [39] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER) long-term follow-up results from an open-label, randomised, phase 3 trial
    Motzer, Robert J.
    Powles, Thomas
    Burotto, Mauricio
    Escudier, Bernard
    Bourlon, Maria T.
    Shah, Amishi Y.
    Suarez, Cristina
    Hamzaj, Alketa
    Porta, Camillo
    Hocking, Christopher M.
    Kessler, Elizabeth R.
    Gurney, Howard
    Tomita, Yoshihiko
    Bedke, Jens
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Apolo, Andrea B.
    Choueiri, Toni K.
    LANCET ONCOLOGY, 2022, 23 (07): : 888 - 898
  • [40] Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
    Choueiri, Toni K.
    Eto, Masatoshi
    Motzer, Robert
    De Giorgi, Ugo
    Buchler, Tomas
    Basappa, Naveen S.
    Mendez-Vidal, Maria Jose
    Tjulandin, Sergei
    Park, Se Hoon
    Melichar, Bohuslav
    Hutson, Thomas
    Alemany, Carlos
    McGregor, Bradley
    Powles, Thomas
    Gruenwald, Viktor
    Alekseev, Boris
    Rha, Sun Young
    Kopyltsov, Evgeny
    Kapoor, Anil
    Gordoa, Teresa Alonso
    Goh, Jeffrey C.
    Staehler, Michael
    Merchan, Jaime R.
    Xie, Ran
    Perini, Rodolfo F.
    Mody, Kalgi
    McKenzie, Jodi
    Porta, Camillo
    LANCET ONCOLOGY, 2023, 24 (03): : 228 - 238
12345